Tumor Markers – Diagnostic Tests for Cancer – New ultra-sensitive platform firstname.lastname@example.org
Looking for partnerships!!!
New Molecular Diagnostics Biosensor features novel type of real-time microarrays that simultaneously detect protein, nucleic acid, and metabolite biomarkers. It requires no or minimal sample preparation and is capable of detecting from a single to several thousands of molecular markers in a small 50-microliter sample of biological fluid, including whole blood. Limit of Detection (LOD) for miRNA is 10^-18M. For proteins and metabolites LOD depends on the assay; for certain antibody-based assays LOD is at the level ~10^-15M. Broad dynamic range of the sensor covers the entire spectrum of clinically significant concentrations.
Classical microarrays operate with small, sub-monolayer amounts of antibodies and probe DNA immobilized on the surface. The signal from the sub-monolayer is small so the low light photodetector e.g. EMCCD camera is necessary for detection. New biosensor uses larger amounts of antibodies per unit area of bioassay spots. The signal is thousand-fold greater due to the use of patented substrate layer. Therefore, CCD cameras of cell phones are sensitive enough to detect the fluorescence signal.
We are looking for collaboration with researchers developing Molecular Diagnostics MDx systems based on fluorescent assays for development of extremely sensitive affordable Point-of-Service or Point-of-Care tools.
Email to email@example.com to learn more
New platform is 1000 times more sensitive than ELISA
The enzyme-linked immunosorbent assay (ELISA) is a test that uses antibodies and color change to identify a substance.
ELISA is a popular format of “wet-lab” type analytic biochemistry assay that uses a solid-phase enzyme immunoassay (EIA) to detect the presence of a substance, usually an antigen, in a liquid sample or wet sample.
The ELISA has been used as a diagnostic tool in medicine and plant pathology, as well as a quality-control check in various industries.
Antigens from the sample are attached to a surface. Then, a further specific antibody is applied over the surface so it can bind to the antigen. This antibody is linked to an enzyme, and, in the final step, a substance containing the enzyme’s substrate is added. The subsequent reaction produces a detectable signal, most commonly a color change in the substrate.
Performing an ELISA involves at least one antibody with specificity for a particular antigen. The sample with an unknown amount of antigen is immobilized on a solid support (usually a polystyrene microtiter plate) either non-specifically (via adsorption to the surface) or specifically (via capture by another antibody specific to the same antigen, in a “sandwich” ELISA). After the antigen is immobilized, the detection antibody is added, forming a complex with the antigen. The detection antibody can be covalently linked to an enzyme, or can itself be detected by a secondary antibody that is linked to an enzyme through bioconjugation. Between each step, the plate is typically washed with a mild detergent solution to remove any proteins or antibodies that are aspecifically bound. After the final wash step, the plate is developed by adding an enzymatic substrate to produce a visible signal, which indicates the quantity of antigen in the sample.
Prostate-specific antigen (PSA) blood test
Prostate-specific antigen (PSA) is a substance made by cells in the prostate gland (both normal cells and cancer cells). PSA is mostly found in semen, but a small amount is also found in the blood. Most healthy men have levels under 4 nanograms per milliliter (ng/mL) of blood. The chance of having prostate cancer goes up as the PSA level goes up.
When prostate cancer develops, the PSA level usually goes above 4. Still, a level below 4 does not guarantee that a man doesn’t have cancer — about 15% of men with a PSA below 4 will have prostate cancer on a biopsy. Men with borderline PSA level between 4 and 10 have about a 1 in 4 chance of having prostate cancer. If the PSA is more than 10, the chance of having prostate cancer is over 50%.
Post time: Sep-02-2017